Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

TLSI

TriSalus Life Sciences (TLSI)

TriSalus Life Sciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TLSI
DateTimeSourceHeadlineSymbolCompany
03/06/202421:00Business WireTriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual MeetingNASDAQ:TLSITriSalus Life Sciences Inc
24/05/202420:05Business WireTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to WarrantsNASDAQ:TLSITriSalus Life Sciences Inc
15/05/202422:00Business WireTriSalus Reports Q1 2024 Financial Results and Business UpdateNASDAQ:TLSITriSalus Life Sciences Inc
07/05/202421:00Business WireTriSalus Life Sciences Appoints Liselotte Hyveled to its Board of DirectorsNASDAQ:TLSITriSalus Life Sciences Inc
07/05/202406:58Business WireTriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference CallNASDAQ:TLSITriSalus Life Sciences Inc
01/05/202406:35Business WireTriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth InitiativesNASDAQ:TLSITriSalus Life Sciences Inc
01/04/202423:00Business WireTriSalus Reports Q4 and Full Year 2023 Financial Results and Business UpdateNASDAQ:TLSITriSalus Life Sciences Inc
26/03/202423:00Business WireTriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific MeetingNASDAQ:TLSITriSalus Life Sciences Inc
21/03/202423:00Business WireTriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific MeetingNASDAQ:TLSITriSalus Life Sciences Inc
12/03/202408:15Business WireTriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial ResultsNASDAQ:TLSITriSalus Life Sciences Inc
07/03/202423:00Business WireTriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101NASDAQ:TLSITriSalus Life Sciences Inc
29/02/202423:00Business WireTriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver TumorsNASDAQ:TLSITriSalus Life Sciences Inc
15/02/202410:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TLSITriSalus Life Sciences Inc
15/02/202410:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TLSITriSalus Life Sciences Inc
15/02/202410:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TLSITriSalus Life Sciences Inc
15/02/202410:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TLSITriSalus Life Sciences Inc
15/02/202410:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TLSITriSalus Life Sciences Inc
26/01/202409:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TLSITriSalus Life Sciences Inc
26/01/202409:23Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TLSITriSalus Life Sciences Inc
26/01/202409:21Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TLSITriSalus Life Sciences Inc
26/01/202409:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TLSITriSalus Life Sciences Inc
06/01/202408:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TLSITriSalus Life Sciences Inc
27/12/202316:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TLSITriSalus Life Sciences Inc
27/12/202316:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TLSITriSalus Life Sciences Inc
27/12/202309:28Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TLSITriSalus Life Sciences Inc
27/12/202309:27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TLSITriSalus Life Sciences Inc
15/11/202300:00Business WireTriSalus Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:TLSITriSalus Life Sciences Inc
08/11/202308:05Business WireTriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference CallNASDAQ:TLSITriSalus Life Sciences Inc
05/11/202305:25Business WireLate-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas IndicationsNASDAQ:TLSITriSalus Life Sciences Inc
04/11/202303:00Business WireTriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:TLSITriSalus Life Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:TLSI